UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

R. Lor Randall, MD, FACS, elaborates on the results of a study and provided insight into future research directions in Ewing sarcoma

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

Pivotal trials, such as the phase 3 FLAURA trial with osimertinib in patients with EGFR-mutant non–small cell lung cancer NSCLC, have demonstrated the significant benefit yielded with targeted therapies.

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

Amputations were found to be associated with Hispanic ethnicity and male sex in patients with neoplasms of the foot.

David R. Gandara, MD has been appointed chief medical officer of the International Society for liquid biopsy, an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management.

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.

R. Lor Randall, MD, FACS, discusses the advantages of rotationplasty for oncologic and non-oncologic indications in children and young adults.

R. Lor Randall, MD, discusses the data from the population-based registry and provided more insight on prognostic factors and survival outcomes for patients with spinal sarcomas.

Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.

Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.

Mehrdad Abedi, MD, discusses the challenges of standard transplant, how Orca-T could overcome some of those limitations, and the potential future of transplant in hematologic malignancies.

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

R. Lor Randall, MD, discusses the intriguing risk-stratification–based trial in NSTRS and how the findings can be used to guide treatment decisions in this pediatric population.

R. Lor Randall, MD, FACS, discusses the rationale and motivation behind tissue-engineered platforms and how they could significantly impact the understanding of how cancer arises in or metastasizes to bone. 

R. Lor Randall, MD, FACS, discusses the concept and prospect of up-front resection in osteosarcoma from the Osteosarcoma Collaborative.

R. Lor Randall, MD, FACS, discusses limb salvage surgeries that have been made possible through 3D printing, and the technological advances that are helping to increase precision and turnaround times.

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

R. Lor Randall, MD, FACS, highlights the various data presented at the annual MSTS meeting and their implications for the future of sarcoma treatment.

In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

Premenopausal women with breast cancer who were previously treated with radiotherapy for a primary childhood, adolescent, or young adult cancer were found to have worse breast cancer–specific survival.